Editorial: Secondary Dyslipidemias

Moses Elisaf, MDRole: (Guest Editor)
Address: Department of Internal Medicine Medical School, University of Ioannina GR 45110 Ioannina Greece +30-2651-0-07509 +30-2651-0-07016 egepi@cc.uoi.gr
Vasilis Tsimihodimos, MDRole: (Co-Guest Editor)
Address: Department of Internal Medicine Medical School, University of Ioannina GR 45 110 Ioannina Greece +30 26510 97509 +30 26510 97016 tsimiho@gmail.com

Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 476
Abstract HTML Views: 532
PDF Downloads: 183
Total Views/Downloads: 1191
Unique Statistics:

Full-Text HTML Views: 309
Abstract HTML Views: 306
PDF Downloads: 128
Total Views/Downloads: 743

© Tsimihodimos and Elisaf; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.


The term “secondary dyslipidemias” is used to describe the quantitative and/or qualitative alterations in lipoprotein metabolism that complicate the course of other medical disorders. Although the precise prevalence of secondary dyslipidemias has not been determined, the increasing incidence of the conditions that predispose to their development (such as obesity, diabetes mellitus, malignancies, end stage renal disease etc) implies that these alterations are very common in the every day clinical practice. Several lines of evidence suggest that the identification and appropriate management of secondary dyslipidemias is of paramount importance. Like primary dyslipidemias, the secondary changes in lipid metabolism significantly increase the risk for cardiovascular events [1, 2] as well as for other disease-specific complications. For example, the dyslipidemia of chronic kidney diseases may accelerate the deterioration of renal function in patients with renal failure [3], whereas diabetic dyslipidemia may increase the risk of acute pancreatitis in genetically predisposed individuals [4]. On the other hand, since the improvement of the underlying disease (if possible) usually results in the correction (at least in part) of lipid abnormalities, the proper identification of a secondary cause of dyslipidemia may help to the avoidance of unnecessary hypolipidemic treatment. In addition, some secondary causes of dyslipidemia (such as hypothyroidism and renal failure) may increase the risk of serious and potentially fatal adverse events after hypolipidemic drug administration [5, 6], thus their exclusion is obligatory prior to the institution of lipid-lowering therapy. Finally, the presence of dyslipidemia or its response to the conventional medical treatment may represent the first clinical sigh of an important underlying medical condition [7].

The most common causes of secondary dyslipidemias as well as the few simple laboratory tests that along with a detailed medical history and a throughout physical examination are needed for their exclusion are presented in the Table 1. This supplement issue of the Open Cardiovascular Medicine Journal is dedicated to the most common forms of secondary dyslipidemias. The pathophysiology, clinical features and the relevant therapeutic options are discussed extensively. We believe that this knowledge is of importance not only for lipid specialists but also for every doctor that deals with dyslipidemic individuals in the primary care setting.

Table 1.

Common Causes of Secondary Dyslipidemias and Their Laboratory Markers

Condition Laboratory test
Diabetes mellitus Fasting glucose
Hypothyroidism Thyroid stimulating hormone (TSH)
Chronic kidney disease Serum creatinine Estimated Glomerular filtration rate (eGFR)
Nephrotic syndrome Dipstick urine examination
Cholestasis Alkaline phosphatase


[1] Betteridge DJ. Diabetic dyslipidemia Am J Med 1994; 96: 25S-31S.
[2] Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment Am J Nephrol 2008; 28: 958-73.
[3] Ritz E, Wanner C. Lipid changes and statins in chronic renal insufficiency J Am Soc Nephrol 2006; 17: S226-30.
[4] Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A. Hypertriglyceridemic pancreatitis: presentation and management Am J Gastroenterol 2009; 104: 984-1.
[5] Kursat S, Alici T, Colak HB. A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism Clin Nephrol 2005; 64: 391-.
[6] Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report Eur J Clin Pharmacol 2009; 65: 1169-74.
[7] Liberopoulos E, Miltiadous G, Elisaf M. Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidism Diabetes Obes Metab 2001; 3: 97-8.